RxDoctor Payments Data

Laura Alvarez Orduz, MD

Internal Medicine · Ft Lauderdale, FLNPI 1023541315

Payments from drug & device makers

$488in general payments, 2019–2025

Across 25 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$159
  • Novo Nordisk$141
  • Pfizer$59
  • Lilly USA, LLC$32
  • Exact Sciences$30
  • Bayer$27
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$488100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen10$159
Novo Nordisk6$141
Pfizer3$59
Lilly USA, LLC2$32
Exact Sciences1$30
Bayer1$27
GSK1$21
Eisai Inc.1$19

How this compares

$488 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$136,197
Medicare patients
297
Services billed
1,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$77,353
EliquisApixaban50$57,693
MounjaroTirzepatide35$37,194
JardianceEmpagliflozin22$28,196
ProliaDenosumab14$24,566
TrulicityDulaglutide17$15,792
Breo ElliptaFluticasone/Vilanterol14$8,678
Atorvastatin Calcium453$4,803
SymbicortBudesonide/Formoterol Fumarate12$4,649
Levothyroxine Sodium256$3,146
Rosuvastatin Calcium218$2,741
Losartan Potassium273$2,588
Metoprolol Succinate156$2,582
Pantoprazole Sodium154$2,227
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide34$2,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$141$77,35369 claims
PfizerEliquis, Paxlovid$59$59,12361 claims
Lilly USA, LLCMounjaro, Trulicity$32$52,98752 claims
AmgenProlia$159$24,56614 claims
GSKBreo Ellipta$21$8,67814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Ft Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →